Overview

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

Status:
Not yet recruiting

Trial end date:
2026-02-01

Target enrollment:

Participant gender:

Summary

This is a single-center, nonrandomized, open-label dose-escalation study followed by dose-expansion of CD19- CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Medical University of South Carolina

Treatments:

Cyclophosphamide
Fludarabine